Technology Opportunities & Ventures
While focus is on header menu items,
press the down arrow to open sub-menu.
press the down arrow to open sub-menu.
2022
Active
Principal Investigators: Marcus Noyes, PhD
Navega is a preclinical stage company developing epigenetic-regulation gene therapies to tackle common diseases. Due to the involvement of NaV1.7 in multiple chronic pain states, Navega is harnessing the power of the epigenome to modify its expression and treat multiple chronic pain indications, including chemotherapy-induced peripheral neuropathy. Other indications in Navega’s pipeline include neurological and ophthalmic diseases.